(Repeats to chain to corrected alerts; no changes to text)

Overview

* Shoulder Innovations Q2 2025 revenue up 33% to $11 mln,

driven

by implant sales

* Net loss widened to $19.2 mln due to preferred stock

warrant

liability changes

* Co completed IPO raising $75 mln, enhancing financial

position

for growth

Outlook

* Shoulder Innovations ( SI ) expects 2025 revenue between $42 mln

and

$44 mln

Result Drivers

* IMPLANT SALES - Revenue growth driven by 34% increase in

implant

system sales

* CUSTOMER EXPANSION - Nearly 50% increase in surgeon

customers

year-over-year

* FINANCIAL POSITION - IPO and convertible notes financing

strengthened balance sheet

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$165.53

Q2 Net -$19.20

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy"

and

the breakdown of recommendations is 4 "strong buy" or "buy", no

"hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical

equipment,

supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Shoulder

Innovations Inc ( SI ) is $18.50, about 14.1% above its September 8

closing price of $15.90

Press Release:

(This story was created using Reuters automation and AI based

on LSEG and company data. It was checked and edited by a Reuters

journalist prior to publication.)